Urofollitropin 75unit powder and solvent for solution for injection ampoules
Urofollitropin is a urinary-derived follicle-stimulating hormone (FSH) that is extracted and purified from human urine samples.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Urofollitropin
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Urofollitropin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Urofollitropin on the MHRA register
Metrodin High Purity 75unit powder and solvent for solution for injection ampoules
Metrodin High Purity 75unit powder and solvent for solution for injection ampoules
WHO defined daily dose (DDD)
75 unit
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 45 studies.
Reviews & meta-analyses: 1 · Randomised trials: 1 · Trials: 6 · 1993–2025
Showing all 45 studies, sorted by most relevant.
Tingting Li
Fertility and Sterility, 2020
Grynberg M, Cedrin-Durnerin I, Raguideau F, et al.
2023
- Follicle Stimulating Hormone, Human
- Ovulation Induction
- Biosimilar Pharmaceuticals
This comparative non-interventional study using data from the French National Health Database (Système National des Données de Santé) investigated real-world (cumulative) live birth outcomes following ovarian stimulation, leading to oocyte pickup with either originator recombinant human follicle-stimulating hormone (r-hFSH) products (alfa or beta), r-hFSH alfa biosimilars, or urinaries including mainly HP-hMG (menotropins), and marginally u-hFSH-HP (urofollitropin). Using data from 245,534 stimulations (153,600 women), biosimilars resulted in a 19% lower live birth (adjusted odds ratio (OR) 0.81, 95% confidence interval (CI) 0.76-0.86) and a 14% lower cumulative live birth (adjusted hazard ratio (HR) 0.86, 95% CI 0.82-0.89); and urinaries resulted in a 7% lower live birth (adjusted OR 0.93, 95% CI 0.90-0.96) and an 11% lower cumulative live birth (adjusted HR 0.89, 95% CI 0.87-0.91) versus originator r-hFSH alfa. Results were consistent across strata (age and ART strategy), sensitivity analysis using propensity score matching, and with r-hFSH alfa and beta as the reference group.
Abstract licence: CC BY
Yu Sun, Chunrong Qu, Kun Qian, et al.
Molecular Pharmaceutics, 2025
- Neoplasms
- Follicle Stimulating Hormone
- Receptors, FSH
Zhao YY, Chen LS, Wei W, et al.
2023
- Urofollitropin
- Semen
- Testosterone
Reactions Weekly, 2025
Reactions Weekly, 2023
Reactions Weekly, 2023
A. Cocci, G. Cito, G. Russo, et al.
Urologia Journal, 2018
- Reproductive Techniques, Assisted
- Sperm Retrieval
- Pregnancy Rate
S. La Vignera, R. Condorelli, R. Cannarella, et al.
Endocrine, 2019
- Testis
- Spermatozoa
- Infertility, Male
E. Lenton, A. Soltan, J. Hewitt, et al.
Human reproduction, 2000
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
3-4 hours
Mechanism
FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
74%
Half-life
3-4 hours
Volume of distribution
17 hours
IM: 17 hours (single dose), 11 hours (multiple doses)
SubQ: 21 hours (single dose), 10 hours (multiple doses)
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
How the body processes this drug — absorption, distribution, metabolism, and elimination
IM: 17 hours (single dose), 11 hours (multiple doses)
SubQ: 21 hours (single dose), 10 hours (multiple doses)
Proteins and enzymes this drug interacts with in the body
PMID:11847099 PMID:24058690 PMID:24692546
Through cAMP production activates the downstream PI3K-AKT and ERK1/ERK2 signaling pathways PMID:24058690
ATC G03GA04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Urofollitropin
Additional database identifiers
Drugs Product Database (DPD)
7649
Drugs Product Database (DPD)
306
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3969
GenAtlas
FSHR
GeneCards
FSHR
GenBank Gene Database
M65085
GenBank Protein Database
182771
Guide to Pharmacology
253
UniProt Accession
FSHR_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72